8-K: Repare Therapeutics Announces Positive Phase 1 Trial Results for Lunresertib and Camonsertib Combination in Gynecologic Cancers

Repare Therapeutics reports promising data from its MYTHIC Phase 1 trial, showing significant response rates for a combination therapy in patients with endometrial and platinum-resistant ovarian cancers.

Summary

• Repare Therapeutics has announced positive results from its MYTHIC Phase 1 clinical trial evaluating the combination of lunresertib and camonsertib (Lunre+Camo) in patients with endometrial cancer and platinum-resistant ovarian cancer (PROC).
• The trial included 51 evaluable patients in the gynecologic cancer expansion cohort, with 27 having endometrial cancer and 24 having PROC.
• In endometrial cancer patients, the overall response rate (ORR) was 25.9%, with a clinical benefit observed in 48.1% of patients, and a 24-week progression-free survival (PFS) of 43%.
• For PROC patients, the ORR was 37.5%, with a clinical benefit observed in 77.3% of patients, and a 24-week PFS of 45%.
• The combination therapy demonstrated a favorable tolerability profile, with the most common adverse event being anemia (26.9%).
• The company has received guidance from the FDA and EMA on its registrational development plans and intends to start a Phase 3 trial in endometrial cancer in the second half of 2025.
• A small contribution of components trial in endometrial cancer is expected to begin in the first quarter of 2025.

Sentiment

Score: 8

Explanation: The document presents very positive clinical trial results with a clear path to potential regulatory approval, indicating a strong outlook for the company's lead drug candidate. The management commentary is also very positive.

Positives

• The combination therapy showed promising efficacy in heavily pre-treated patients with both endometrial and platinum-resistant ovarian cancers.
• The 24-week progression-free survival rates were encouraging, with 43% in endometrial cancer and 45% in PROC.
• The tolerability profile of Lunre+Camo was favorable compared to current and emerging therapies.
• The company has received positive feedback from regulatory agencies, supporting the potential for accelerated approval.
• The biomarker-driven approach targets specific genetic mutations, potentially leading to more effective treatments.

Negatives

• Anemia was the most common adverse event, occurring in 26.9% of patients.
• Some patients experienced other adverse events such as nausea, vomiting, rash, and fatigue.
• The trial is still in Phase 1, and further studies are needed to confirm these results.

Risks

• The success of the Phase 1 trial does not guarantee success in later clinical trials.
• Macroeconomic conditions, including global conflicts, could impact the company's business and clinical trials.
• Unexpected safety or efficacy data could emerge during future clinical trials.
• Changes in the regulatory environment or unexpected litigation could affect the company's plans.
• Clinical trial site activation or enrollment rates could be lower than expected.

Future Outlook

Repare Therapeutics plans to initiate a Phase 3 registrational trial for Lunre+Camo in endometrial cancer in the second half of 2025 and a small contribution of components trial in the first quarter of 2025. The company is also exploring the potential of Lunre+Camo in other tumor types.

Management Comments

• Lloyd M. Segal, President and CEO, stated that the results support the potential for Lunre+Camo to make a real, positive difference if approved, particularly as a chemotherapy alternative.
• Maria Koehler, MD, PhD, Chief Medical Officer, expressed confidence in the potential to bring Lunre+Camo to patients and looks forward to building on the promising data through registrational clinical trials.
• Brian Slomovitz, MD, MS, FACOG, noted the urgent need for new treatment options for patients with recurrent gynecologic cancers and highlighted the potential of Repare's approach.

Industry Context

This announcement is significant as it addresses the unmet need for effective treatments in advanced endometrial and platinum-resistant ovarian cancers, where current options are limited, especially after prior immunotherapy and chemotherapy. The biomarker-driven approach aligns with the trend towards personalized medicine in oncology.

Comparison to Industry Standards

• The reported ORR of 25.9% in endometrial cancer and 37.5% in PROC compares favorably to historical data for single-agent chemotherapy in these heavily pre-treated populations.
• The 24-week PFS of 43% in endometrial cancer and 45% in PROC is competitive with emerging antibody-drug conjugates (ADCs) in similar patient populations, such as sacituzumab govitecan, while potentially offering a better tolerability profile.
• The company is targeting a similar market opportunity to Mirvetuximab in the BM+ subset of patients.
• The trial results suggest a potential alternative to chemotherapy-based treatments, which are often associated with significant side effects.

Stakeholder Impact

• Shareholders: The positive trial results and potential for regulatory approval are likely to positively impact the company's stock price.
• Patients: The development of Lunre+Camo offers a potential new treatment option for patients with advanced endometrial and ovarian cancers.
• Employees: The progress of the clinical trial and the potential for commercialization could lead to job growth and opportunities within the company.
• Healthcare providers: The new treatment option could provide a valuable tool for managing patients with these cancers.

Next Steps

• Initiate a small contribution of components trial in endometrial cancer in the first quarter of 2025.
• Start the first Phase 3 Lunre+Camo trial in endometrial cancer in the second half of 2025.
• Submit the final Phase 3 trial protocols for regulatory clearance imminently.

Key Dates

Keywords

lunresertib, camonsertib, endometrial cancer, ovarian cancer, precision oncology, PKMYT1 inhibitor, ATR inhibitor, MYTHIC trial, Phase 1 trial, clinical trial, biomarker, gynecologic cancer, synthetic lethality